title: AChR-specific immunosuppressive therapy of myasthenia gravis.
abstract: Myasthenia gravis (MG) is an organ-specific autoimmune disease characterized by muscle fatigability. In most cases, it is mediated by autoantibodies targeting muscle nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction. Experimental autoimmune myasthenia gravis (EAMG) is an animal model for MG, which is usually induced by immunization with AChR purified from fish electric organ. Pathological autoantibodies to AChRs are directed at the extracellular surface, especially the main immunogenic region (MIR). Current treatments for MG can help many but not all patients. Antigen-specific immunosuppressive therapy for MG that specifically suppresses the autoimmune response without affecting the entire immune system and avoids side effects of general immunosuppression is currently unavailable. Early attempts at antigen-specific immunosuppression for EAMG using AChR extracellular domain sequences that form epitopes for pathological autoantibodies risked provoking autoimmunity rather than suppressing it. We discovered a novel approach to specific immunosuppression of EAMG with a therapeutic vaccine consisting of bacterially-expressed human AChR cytoplasmic domains, which has the potential to specifically suppress MG without danger of causing exacerbation. This approach prevents development of chronic EAMG when initiated immediately after the acute phase of EAMG, and rapidly reverses established chronic EAMG when started during the chronic phase of EAMG. Successfully treated rats exhibited long-term resistance to re-induction of EAMG. In this review we also discuss the current understanding of the mechanisms by which the therapy works. Vaccination with AChR cytoplasmic domains in adjuvant is promising as a safe, antigen-specific, potent, effective, rapidly acting, and long lasting approach to therapy of MG.
authors.affiliation: Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, PA, USA. Electronic address: luoj3@mail.med.upenn.edu.
authors.forename: Jie
authors.initials: J
authors.lastname: Luo
authors.affiliation: Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, PA, USA.
authors.forename: Jon
authors.initials: J
authors.lastname: Lindstrom
mesh_terms: D000818:Animals; D001323:Autoantibodies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009157:Myasthenia Gravis / Q000188:drug therapy*; D017434:Protein Structure, Tertiary; D011950:Receptors, Cholinergic / Q000378:metabolism*; D014611:Vaccination
chemical_list: D001323:Autoantibodies; D007166:Immunosuppressive Agents; D011950:Receptors, Cholinergic
keywords: Acetylcholine receptor; Antibody; Cytoplasmic domain; EAMG; Immunosuppression